Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol

Long-term liver toxicities do not appear to be a significant problem for Kynamro, a second-generation anti-sense drug that manages severe high cholesterol in patients with a rare inherited genetic disease, the companies sponsoring the drug, Sanofi/Genzyme Corp. and partner Ionis Pharmaceuticals Inc. say.

Results of a two-year, ongoing, open extension study incorporating patients from a Phase III program for the drug found that metrics measuring liver function were consistent with the much shorter randomized, controlled Phase III studies, which had six months duration